Abstract:Background & aims: Bile acid nuclear receptor farnesoid X receptor (FXR) is a key molecular mediator of many metabolic processes, including the regulation of bile acid, lipid and glucose homeostasis. A significant component of FXR-mediated events essential to its biological activity is attributed to induction of the enteric endocrine hormone fibroblast growth factor (FGF)19 or its rodent ortholog, FGF15. In this report, we compared the properties of human FGF19 and murine FGF15 in the regulation of hepatocarcinogenesis and metabolism in various mouse models of disease. Methods: Tumorigenicity was assessed in three mouse models (db/db, diet-induced obese, and multi-drug resistance 2 [Mdr2]-deficient) following continuous exposure to FGF19 or FGF15 via adeno-associated viral-mediated gene delivery. Glucose, hemoglobin A1c and β-cell mass were characterized in db/db mice. Oxygen consumption, energy expenditure, and body composition were evaluated in diet-induced obese mice. Serum levels of alkaline phosphatase, alanine aminotransferase, and aspartate aminotransferase were assessed in Mdr2-deficient mice. Expression profiles of genes encoding key proteins involved in bile acid synthesis and hepatocarcinogenesis were also determined. Results: Both FGF15 and FGF19 hormones repressed bile acid synthesis (p<0.001 for both). However, murine FGF15 lacked the protective effects characteristic of human FGF19 in db/db mice with overt diabetes, such as weight-independent HbA1c-lowering and β-cell-protection. Unlike FGF19, FGF15 did not induce hepatocellular carcinomas (HCC) in three mouse models of metabolic diseases (db/db, diet-induced obese, and multi-drug resistance 2 [Mdr2]-deficient mice), even at supra-pharmacological exposure levels. Conclusions: Fundamental species-associated differences between FGF19 and FGF15 may restrict the relevance of mouse models for the study of the FXR/FGF19 pathway, and underscore the importance of clinical assessment of this pathway, with respect to both safety and efficacy in humans. Lay summary: Activation of the nuclear receptor, FXR, leads to the production of a hormone called fibroblast growth factor 19 (FGF19) and subsequently regulation of multiple metabolic processes. Synthetic activators of FXR have been recently approved or are currently in clinical development for treatment of chronic liver diseases, including primary biliary cholangitis (PBC) and non-alcoholic steatohepatitis (NASH). The safety of these activators was partly assessed in mice exposed for prolonged periods of time. However, the results of this study show that mouse FGF15 and human FGF19 exhibit fundamentally different biological activities in mice. This could raise the concern of relying on rodent models for safety assessment of FXR activators. The potential risk of HCC development in patients treated with FXR agonists may need to be monitored.

Cereblon regulates the production of hepatic fibroblast growth factor 23 in diabetes

Effects of Fibroblast Growth Factor Inducible 14 (fn14) on High Glucose Induced-Cardiomyocyte Hypertrophy

Cereblon (CRBN) Deletion Reverses Streptozotocin Induced Diabetic Osteoporosis in Mice.

Regulation of hepatic gluconeogenesis by nuclear factor Y transcription factor in mice

Novel Mechanism of Transcriptional Regulation of Cell Matrix Protein Through CREB.

Cereblon harnesses Myc-dependent bioenergetics and activity of CD8+ T lymphocytes

Cereblon Suppresses the Lipopolysaccharide-Induced Inflammatory Response by Promoting the Ubiquitination and Degradation of C-Jun

Cereblon deficiency ameliorates carbon tetrachloride-induced acute hepatotoxicity in HepG2 cells by suppressing MAPK-mediated apoptosis

Hepatocyte FRS2 alpha is Essential for the Endocrine Fibroblast Growth Factor to Limit the Amplitude of Bile Acid Production Induced by Prandial Activity

The novel intracellular protein CREG inhibits hepatic steatosis, obesity, and insulin resistance

Connexin43 regulates high glucose-induced expression of fibronectin, ICAM-1 and TGF-β1 via Nrf2/ARE pathway in glomerular mesangial cells.

Mbnl1-mediated Alternative Splicing of Circmlxipl Regulates Rbbp6-involved ChREBP Turnover to Inhibit Lipotoxicity-Induced Β-Cell Damage

Ablation of Brg1 in fibroblast/myofibroblast lineages attenuates renal fibrosis in mice with diabetic nephropathy

115-LB: Liver-Derived FGF21 Mediates the Promoting Effect of Glucagon Receptor Antagonism on Beta-Cell Regeneration in Type 2 Diabetic Mice

Ciliary Neurotrophic Factor Receptor Alpha Subunit-Modulated Multiple Downstream Signaling Pathways In Hepatic Cancer Cell Lines And Their Biological Implications

Cereblon Promotes the Ubiquitination and Proteasomal Degradation of Interleukin Enhancer-Binding Factor 2

Fibroblast growth factor 21 as an emerging metabolic regulator: clinical perspectives

Fibroblast growth factor 21 improves hepatic insulin sensitivity by inhibiting mammalian target of rapamycin complex 1 in mice

Fibroblast Growth Factor 21 Improves Glucose Homeostasis Partially Via Down-Regulation of Na+-d-glucose Cotransporter SGLT1 in the Small Intestine.

Orphan Nuclear Receptor ERRγ is a Key Regulator of Human Fibrinogen Gene Expression.

Mouse species-specific control of hepatocarcinogenesis and metabolism by FGF19/FGF15